Bydureon Bcise

Active Ingredient(s): Exenatide Synthetic
FDA Approved: * October 20, 2017
Pharm Company: * ASTRAZENECA AB
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Bydureon Bcise Overview

Exenatide (marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day.[1] A once-weekly injection has been approved as of January 27, 2012 under the tra...

Read more Bydureon Bcise Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Byetta

Recent Bydureon Bcise Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Exenatide Synthetic
  • For Suspension, Extended Release: 2mg, 2mg/vial
  • Injection: 2mg, 300mcg/1.2ml (250mcg/ml), 300ugm/1.2ml (250ugm/ml), 300ugm/1.2ml(250ugm/ml), 600mcg/2.4ml (250mcg/ml), 600ugm/2.4ml (250ugm/ml), 600ugm/2.4ml(250ugm/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Exenatide Synthetic or a similar ingredient: (3 results)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 19 November 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.